Home / Treatments / Anti-virals
Anti-virals denials: what the review data shows
Independent reviewers have decided 1,351 published cases where an insurer denied Anti-virals — and they overturned the insurer 81.4% of the time. A denial for Anti-virals is a starting position, not a final answer.
Published decisions
1,351
2001–2026
Overturned
81.4%
1,100 denials reversed
Conditions behind anti-virals denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Hepatitis | 1,282 | 83.4% |
| AIDS HIV | 13 | 61.5% |
| Viral Infection | 9 | 33.3% |
| RSV | 6 | 66.7% |
| Cirrhosis | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 1,333 | 81.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 18 | 44.4% |
Typical time to a decision
18 days
Most land between 11 and 21 days
Handled as urgent
18.4%
Expedited when a delay would cause harm
Recent direction
Rising
57.1% → 72.7% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mavyret for treatment of the enrollee’s chronic hepatitis C virus (HCV), genotype 1a. Findings: The physician reviewer found that according to the most recent joint guidelines issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), all patients with chronic hepatitis C should be treated except those with limited life expectancy due to non-liver-related conditions. The guidelines recommend that all patients should be treated, regardless of fibrosis stage. As ultrasound elastography showed a lack of cirrhosis, thus this patient should be treated as a non-cirrhotic patient. The guidelines recommend that non-cirrhotic treatment naive genotype 1a patients should be treated with Mavyret.
Nature of Statutory Criteria/Case Summary: An enrollee has requested Harvoni for treatment of his hepatitis C virus (HCV). Findings: The physician reviewer found that per the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) treatment guidelines, there is only one treatment option for this patient in whom previous sofosbuvir plus ribavirin with or without peginterferon treatment has failed, and has no cirrhosis. “Daily fixed-dose combination of ledipavir (90 mg)/sofosbuvir (400 mg) with weight-based ribavirin for 12 weeks is recommended for patients without cirrhosis” is recommended as a Class IIb, Level C rating. AASLD/IDSA states “To date, clinical experience and trial data on the retreatment of such patients are very limited.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
A 48-year-old male enrollee has requested for an additional 12 weeks of Pegasys and ribavirin for treatment of his hepatitis C virus. Findings: The physician reviewer found that the current approved treatment for hepatitis C is pegylated interferon (Pegasys) plus ribavirin for a total of 48 weeks in genotype-1 patients. Some studies have suggested that a longer treatment period may be warranted in those patients who have a late documented viral clearance while on therapy. Currently, a 12-week time point is used to determine the presence of an early viral response (EVR); however, many studies indicate that a 4-week point may also be useful in predicting a response to 48 weeks of therapy.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for intramuscular (IM) amino acids methionine, proline, and cystine; placement in a treatment program for chronic Epstein-Barr virus (EBV) using lysine, anti-virals, and rest; and paracervical prolotherapy with neck tracking and physical therapy. Per the current evidence-based peer-reviewed medical literature, treatment with intramuscular (IM) amino acids and prolotherapy are not recommended for patients with fibromyalgia, spine pain, Ehlers-Danlos syndrome, or any of the patient’s listed diagnoses in the medical records.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Anti-viralswhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.